DSM Opens New Biopharmaceutical Manufacturing Facility in Australia - - BioPharm International

ADVERTISEMENT

DSM Opens New Biopharmaceutical Manufacturing Facility in Australia



Untitled Document

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has opened a new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia. The facility was built in partnership with Biopharmaceuticals Australia with cooperation from the government of Queensland and the Commonwealth of Australia.

The Brisbane facility offers cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing.
DSM Biologics, the business unit of DSM Pharmaceutical Products that operates the Brisbane facility, also offers process development and cGMP manufacturing in Groningen, The Netherlands. DSM previously announced contracts for the Brisbane site with DecImmune Therapeutics of Cambridge, Massachusetts, Recepta Biopharma of São Paulo, Brazil, Paranta Biosciences of Melbourne, Australia, and Opthea of Melbourne, Australia. The Brisbane facility has an output capability of 500 kg and has expansion space available for further capacity utilization.

Source: DSM Pharmaceutical

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here